---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006393"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:25:33.756765+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M

## Summary
- Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).
- Non-GAAP adjusted net income $60.4M ($1.03 diluted EPS) vs $50.7M ($0.88) YoY.
- Reaffirms FY2025 revenue guidance $820-$860M; cash and investments >$600M.
- ZYN002 Phase 3 in Fragile X completed recruitment; topline data on track for Q3 2025.
- Pitolisant HD Phase 3 registrational trials in narcolepsy & IH on track to initiate Q4 2025.

## SEC filing metadata
- accession: 0001558370-25-006393
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/0001558370-25-006393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006393
- JSON: https://secwatch.observer/filing/0001558370-25-006393.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.